CAS 641571-10-0

Nilotinib

Description:

Nilotinib is a targeted therapy medication primarily used in the treatment of chronic myeloid leukemia (CML) that is resistant or intolerant to prior therapies. It is classified as a tyrosine kinase inhibitor (TKI) and specifically inhibits the BCR-ABL fusion protein, which is responsible for the uncontrolled proliferation of leukemic cells. Nilotinib is characterized by its high selectivity for BCR-ABL, which minimizes off-target effects and enhances its therapeutic efficacy. The compound is typically administered orally and is known for its favorable pharmacokinetic profile, including good absorption and a long half-life, allowing for once or twice daily dosing. Common side effects may include hematologic toxicities, gastrointestinal disturbances, and metabolic changes. Nilotinib's chemical structure includes a pyrimidine ring and a phenyl group, contributing to its potency and specificity. As a second-generation TKI, it represents an advancement over earlier treatments, providing an important option for patients with specific genetic mutations associated with CML.

Formula: C₂₈H₂₂F₃N₇O

InChI: InChI=1/C28H22F3N7O/c1-17-5-6-19(10-25(17)37-27-33-9-7-24(36-27)20-4-3-8-32-14-20)26(39)35-22-11-21(28(29,30)31)12-23(13-22)38-15-18(2)34-16-38/h3-16H,1-2H3,(H,35,39)(H,33,36,37)

InChI key: InChIKey=HHZIURLSWUIHRB-UHFFFAOYSA-N

SMILES: C(F)(F)(F)C=1C=C(C=C(NC(=O)C2=CC(NC=3N=C(C=CN3)C=4C=CC=NC4)=C(C)C=C2)C1)N5C=NC(C)=C5

Synonyms:

• 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl]benzamide
• 4-Methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzamide
• 4-Methyl-N-[3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl]-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]benzamide
• 4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}benzamide
• 4-methyl-N-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4 -pyridin-3-ylpyrimidin-2-yl)amino]benzamide Nilotinib(TINIBS )
• Amn 107
• Benzamide, 4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-
• Nilotinib
• Nilotinib & its intermediates (Developing)
• Nilotinib for research
• Nilotinib, AMN107, Tasigna
• Tasigna
• Nilotinib(TINIBS )
• 4-methyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)benzamide

Nilotinib

CAS: 641571-10-0

Nilotinib (AMN107) is a Bcr-Abl tyrosine kinase inhibitor. Nilotinib has antitumor activity and may be used in CML. Cost-effective and quality-assured.

Formula: C₂₈H₂₂F₃N₇O

Purity: 99.89% - >99.99%

Color and Shape: Off-White Solid

Molecular weight: 529.52

Ref: TM-T1524

Nilotinib

CAS: 641571-10-0

Nilotinib

Purity: 98%

Molecular weight: 529.52g/mol

Ref: 54-PC109104

Nilotinib

CAS: 641571-10-0

Formula: C₂₈H₃₃F₃N₇O

Color and Shape: Pale Yellow Solid

Molecular weight: 529.53

Ref: 4Z-N-311

Nilotinib

CAS: 641571-10-0

Formula: C₂₈H₂₂F₃N₇O

Purity: ≥ 98.0%

Color and Shape: White to beige or pale yellow powder

Molecular weight: 529.52

Ref: 7W-GP5854

Nilotinib

CAS: 641571-10-0

Nilotinib

Purity: ≥98%

Molecular weight: 529.52g/mol

Ref: 54-BUP14717

Nilotinib

CAS: 641571-10-0

Formula: C₂₈H₂₂F₃N₇O

Purity: >95.0%(T)(HPLC)

Color and Shape: White to Light yellow powder to crystal

Molecular weight: 529.53

Ref: 3B-N1296

Nilotinib

CAS: 641571-10-0

Applications Nilotinib (AMN1O7) might be useful in treatment of chronic myelogenous leukemia. It is a COVID19-related research product.
References Corbin, A., et al.: J. Biol. Chem., 277, 32214(2002), Golemovic, M., et al.: Clin. Cancer Res., 11, 4941 (2005), Gleixner, K., et al.: Blood, 107, 752 (2006), Nicolini, F., et al.: Leukemia, 20, 1061 (2006),

Formula: C₂₈H₂₂F₃N₇O

Color and Shape: Light Yellow To Beige

Molecular weight: 529.52

Ref: TR-N465300

Nilotinib - Bio-X ™

CAS: 641571-10-0

Nilotinib is tyrosine kinase inhibitor drug that is used to treat chronic myeloid leukemia (CML). It inhibits the activity of the BCR-ABL protein kinase, which is involved in the development of CML. Additionally, it inhibits PDGF and c-kit for the potential treatment of various leukemias.

Formula: C₂₈H₂₂F₃N₇O

Purity: Min. 95%

Color and Shape: Powder

Molecular weight: 529.52 g/mol

Ref: 3D-BN164654

Nilotinib

CAS: 641571-10-0

ABL1/BCR and KIT tyrosine kinase inhibitor; PDGFRs and DDR receptor inhibitor

Formula: C₂₈H₂₂F₃N₇O

Purity: Min. 98 Area-%

Color and Shape: White Powder

Molecular weight: 529.52 g/mol

Ref: 3D-FM10831

4-Methyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)benzamide

CAS: 641571-10-0

Formula: C₂₈H₂₂F₃N₇O

Purity: 95.0%

Color and Shape: Solid

Molecular weight: 529.527

Ref: 10-F079266